Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 33,776 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 33,776 shares of Werewolf Therapeutics stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $0.93, for a total value of $31,411.68. Following the completion of the transaction, the director owned 3,482,104 shares of the company’s stock, valued at approximately $3,238,356.72. This represents a 0.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Thursday, November 20th, Luke Evnin sold 26,411 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $23,505.79.
• On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $40,012.04.
• On Monday, November 17th, Luke Evnin sold 36,621 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total value of $34,789.95.
• On Friday, November 14th, Luke Evnin sold 39,560 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $36,790.80.
• On Thursday, November 13th, Luke Evnin sold 58,372 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $57,204.56.
• On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total transaction of $28,450.09.
• On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total transaction of $40,832.52.
• On Monday, November 10th, Luke Evnin sold 31,172 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.18, for a total transaction of $36,782.96.
• On Friday, November 7th, Luke Evnin sold 43,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total transaction of $48,784.50.
• On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total value of $42,285.87.

Werewolf Therapeutics Trading Down 4.3%

HOWL traded down $0.04 during trading hours on Friday, reaching $0.82. 644,797 shares of the company’s stock traded hands, compared to its average volume of 503,091. The firm has a 50-day moving average price of $1.54 and a 200 day moving average price of $1.33. The firm has a market capitalization of $39.71 million, a PE ratio of -0.50 and a beta of 0.72. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. MPM Asset Management LLC boosted its holdings in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after buying an additional 25,688 shares in the last quarter. MPM Bioimpact LLC raised its stake in shares of Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after acquiring an additional 20,799 shares in the last quarter. Bank of America Corp DE lifted its position in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares during the last quarter. Vanguard Group Inc. lifted its position in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Werewolf Therapeutics in the second quarter valued at approximately $409,000. 64.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HOWL. JMP Securities decreased their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Bank of America reduced their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Finally, Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.